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Background/objective: Fatigue, cognitive, and affective disorders are relevant
symptoms in multiple sclerosis (MS). The treatment with Natalizumab has a positive effect
on physical disabilities in patients with relapsing–remitting MS (RRMS). Some studies
describe improvements in cognition and fatigue over 1 year of treatment. Only little is
known about longer treatment effects especially on fatigue, and also on cognition and
mood. Therefore, the present retrospective open label observational study investigates
the effect of Natalizumab on fatigue, attention, and depression over a treatment period of
2 years.
Methods: About 51 RRMS patients who were treated with Natalizumab (male=11,
female=40; mean age: 33. 99. 1 years) were included. The neuropsychological
assessment consisted of different tests of attention (TAP: alertness, divided attention,
flexibility, SDMT, PASAT), fatigue (WEIMuS, FSMC), and depression (CES-D). The assess-
ments occurred immediately before the first administration of Natalizumab, after 1 and
2 years of treatment.
Results: Significant improvements were found in aspects of attention and depression
from baseline to follow-up 1 [alertness: reaction time (RT) cued, p<0.05; divided
attention: visual RT, p<0.05; SDMT: p=0.05; CES-D: p<0.05] and from baseline to
follow-up 2 (divided attention: visual RT: p<0.001; errors: p<0.01, omissions: p<0.05;
flexibility: RT, p<0.05; SDMT: p<0.01; CES-D: p<0.05). No significant changes were
detected in fatigue, probably because of the small sample size, especially in the second
year of treatment (WEIMuS: N=16, FSMC: N=8).
Conclusion: The results show a positive effect of Natalizumab on attention in patients
with RRMS, and for the first time, also in depression after 2 years of observation,
and support the efficacy of the treatment over 2 years. More research is needed for
fatigue.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelinat-
ing disease of the central nervous system, which causes myelin
destruction and axonal loss in the brain and spinal cord, and leads
to different visible and invisible symptoms, such as MS-related
fatigue, cognitive dysfunctions, and depression (1, 2). Fatigue
affects up to 90% of MS patients in all disease stages (3, 4), has
significant socioeconomic consequences, and is a relevant factor
of diminished quality of life among patients withMS (5). Different
biological and psychological models exist regarding the multifac-
torial etiology of fatigue (6). Inflammation, demyelination, and
also behavioral variables such as anxiety, depression, and reduced
activity are associated with fatigue (7).
In addition, cognitive dysfunctions are common in MS (8) and
can appear in all disease stages (9–11). The association to fatigue
is unclear. Whereas some studies describe an association between
fatigue and cognitive impairment (12, 13), in other studies no
correlation was found (14, 15). The prevalence rates vary between
43 and 70% depending on the research setting, the characteristics
of the clinical sample, and the used assessment tools (16). Most
impaired cognitive domains in MS are information processing
speed and complex attention, verbal and non-verbal memory, and
executive functions, aswell as visual spatial functions. Intelligence,
language, and semantic memory aremostly preserved (15, 17, 18).
Depression in MS has a prevalence rate up to 50% (19, 20), and
is associated with fatigue as well as cognitive functions (1, 21). The
differentiation between fatigue and depression is often difficult
and symptoms of depression can be mistaken as fatigue.
Different studies describe a beneficial effect of immunmod-
ulatory treatments on cognitive functions by containing the
development of new cerebral lesions or reducing brain atrophy
(22–24). Less clearly are the effects of immunmodulatory ther-
apies on fatigue and depression. Metz et al. (25) report a more
beneficial effect of glatirameracetat than β interferon on fatigue
after 6months of treatment. Other studies found no relationship
between depression and treatment with interferons (26, 27). One
study reported decreased quality of life, worsened fatigue, and
depression under treatment with β interferon (28).
Natalizumab (NTZ) is a humanized monoclonal antibody, and
is used as monotherapy in relapsing–remitting MS (RRMS) in
severe courses. NTZ has positive effects on physical disabilities,
in reducing the relapse rate and magnetic resonance imaging
(MRI) detectable disease activity (29, 30). Past studies investigated
the effect of NTZ on cognition and partially also on depression
and fatigue over the observational periods of 6months to 1 year
(31–35). Putzki et al. (36) encompassed fatigue and depressive
symptoms at baseline immediately before the treatment with NTZ
and 6months later. About 46% of the 42 treated patients decreased
in the Modified Fatigue Impact Scale [MFIS, (37)] and 39%
showed improvements in the Fatigue Severity Scale [FSS, (38)]. No
changes were detected in the Beck0s Depression Inventory [BDI,
(39)] over the observational period. Another multicenter study
(34) with 195 RRMS patients found significant improvements in
fatigue after 12months of treatment with NTZ. Fatigue was mea-
sured with the Fatigue Scale for Motor and Cognitive Functions
[FSMC, (40)]. All of the secondary outcomes improved over time,
including quality of life, sleepiness, depression, cognition, and the
degree of disability.
Little is known about the treatment effects of NTZ for longer
treatment periods and the effect on specific cognitive domains.
Iaffaldano et al. (41) found improvements in fatigue and cognition
after 1 year of treatment and partially for fatigue also after 2 years
of NTZ treatment. Fatigue was measured with the FSS (38) and
improved from initially 45% of patients with fatigue to 29% after
1 year of treatment. This effect remained stable in the second
year of treatment. Cognitive impairment, measured by Rao’s Brief
Repeatable Battery (BRB) and Stroop Test (42), improved signifi-
cantly only in the first year of treatment (29% to 19% decrease); in
the second year, the effect was not statistical significant.
Against the background of the results in the literature and in
comparison and addition to the hitherto published data, the aim
of the present retrospective open label observational study was the
investigation of the effect of NTZ on fatigue, different aspects of
cognition, and depression over a treatment period of 1 and 2 years.
Materials and Methods
Study Design and Sample
The present retrospective open label observational study was con-
ducted at two departments of neurology (Teupitz, Wermsdorf) in
Germany. Both are accredited MS centers from the German Mul-
tiple Sclerosis Association (DMSG). All patients were explained in
detail prior to the first application of NTZ through competent MS
nurses and the attending physicians; and provided their oral and
written informed consent for all procedures; the participation and
the accompanying required comprehensive clinical assessment.
All used data weremade anonymous andwere transferredwithout
names, addresses, and date of birth in an evaluation file. No study
code was used. Consequently, a subsequent assignment from the
data to a special patient record is not possible.
Data of 51 (Teupitz: N= 33, Wermsdorf, N = 18) patients
with a relapsing remitting course of MS (43), who were treated
monthly with a constant dose of 300mg NTZ according to the
german pharmaceutical indications over the course of 1 year, were
included. Thirty one of these patients continued the application
with NTZ for a second year of treatment. The remaining 20
cases completed the second treatment year after time of statistical
analysis in the course of the ongoing year. The detailed description
of the sample is shown in Table 1. Before the treatment with NTZ,
most patients had applied other treatment options. Twenty seven
patients received Interferon-β1a, 24 received Interferon-β1b, 12
patients were treated with Glatiramer acetate, and 4 patients got
Mitoxantron.
Clinical and Cognitive Assessments
Prior to the first application of NTZ, every patient received a
standardized comprehensive clinical assessment, consisting of
MRI, chest X-ray, gynecological, respectively, urologic check-up,
inspection of the skin, determination of visual acuity, sonogra-
phy of the epigastrum, different blood tests, JVC-antibody test,
and the neurological examination with assessment of the degree
of disability measured by EDSS (44). The treatment with NTZ
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TABLE 1 | Description of the sample.
Baseline Year 1 Year 2
N 51 51 31
Age 33.99.1a
Gender (male/female) 11/40 11/40 7/24
Disease duration (years) 5.34.8a
EDSSb 4.01.6a 3.81.7 3.91.7
Number of prior medications 1.30.8
Time to follow-up (years) 0.90.2 2.00.4
Depression-index (CES-D) 18.510.1 16.610.2 16.68.9
Cut-off>22= 15
Fatigue-index (FSMC) 65.217.5 65.820.5 63.420.5
Cut-off43= 9
Fatigue-index (WEIMuS) 32.715.7 29.618.3 29.620.2
cut-off32= 15
aMeanSD.
bExpanded Disability Status Scale (44).
Prior medications: interferon-β1a, interferon-β1b, glatiramer acetate, Mitoxantron.
WEIMuS, Würzburg Fatigue Inventory for MS (45); FSMC, Fatigue Scale for Motor and
Cognitive Functions (40); CES-D, Center for Epidemiological Studies-Depression Scale
(46, 47).
included yearly follow-up examinations of MRI, blood test, cog-
nitive assessment, JVC-antibody test, and neurological examina-
tion (EDSS).
Furthermore, all patients obtained an annually comprehensive
cognitive testing for detecting changes in cognition during the
treatment of NTZ. The cognitive assessment was performed by
trained psychologists according to standard procedures. All cogni-
tive tests were performed immediately before the first infusion of
NTZ, after 1 and 2 years of application with a fixed test battery. All
examinations at eachmeasurement point start with the assessment
of fatigue and depression. For the evaluation of fatigue, the Fatigue
Scale for Motor and Cognitive Functions [FSMC; (40)] and the
Würzburg Fatigue Inventory for MS [WEIMuS; (45)] were used.
The FSMC consists of 20 items and is a five-stage rating scale
without time limit for evaluation. The cut-off for fatigue is 43.
On the other hand, the WEIMuS estimates fatigue in the course
of the last week. This questionnaire consists of 17 items and has
also a 5-stage rating scale with a cut-off for fatigue of32. For the
assessment of depressive symptoms, the 20 items of the Center for
Epidemiological Studies-Depression Scale [CES-D; (46, 47)] were
used. The cut-off for a clinical relevant depression is >22. This
cut-off achieves a high sensitivity (82–84%) and specificity (47).
In everyday clinical practice, the neuropsychological exami-
nation included the computerized Attention Test Battery [TAP,
Version 2.2; (48)], with the subtests alertness (responsiveness),
divided attention and flexibility, as well as the Symbol Digit
Modalities Test [SDMT; (49)], for the assessment of different
aspects of attention and information processing speed. Addition-
ally, verbal memory was tested using the Auditory Verbal Learn-
ing test (50) and non-verbal memory using the “Diagnosticum
fuer Cerebralschaedigung” [DCS; (51)]. Visuospatial abilities were
assessed by the Rey–Osterrieth Complex Figure Test (ROCF)
using the Taylor Scoring System (52). A Word Fluency Test was
used for a screening of executive functions with the subtests
animals, S-words, and alternating G- and R-words (53). In addi-
tion, a recognition vocabulary test was used to assess premorbid
aspects of intelligence [German Vocabulary Scale, WST; (54)]. All
cognitive tests were given in a fixed order: SDMT, AVLT (learning,
interference), ROCF, three subtests of the TAP, AVLT (recall and
recognition), DCS, fluency, WST.
Statistical Analysis
Statistical analyses were performed with the Statistical Package
for the Social Sciences (SPSS Inc., Chicago, IL, USA). Only the
data concerning fatigue, depression, and attention were analyzed.
Tests for memory and executive functions were not analyzed
because of the missing control group, against the background
of learning effects. Variables were reported by using descriptive
statistics. Differences from baseline to follow-up measurement
points (year 1, year 2) were evaluated using the t-test for paired
samples and the Wilcoxon Rank test. The statistical analysis for
2 years is based only on those patients who remained in the study
the whole time (N = 31), because in the utilized paired sample
t-test only those cases were included for which data for both
time points were available. The p-value <0.05 was considered as
statistical significant on one-sided testing. Not all tests could be
given at all measurement points because of limited physical and
cognitive skills. The following 10 test-parameters were used for
the statistical analysis:
1. Attention Test Battery
Alertness:
median reaction time (AL RT), measured inmilliseconds (ms).
median reaction time cued (AL RT cued) in ms
(responsiviness).
Divided Attention:
median divided attention reaction time visual (Divid Att RT
vis) in ms.
median divided attention reaction time auditory (Divid Att RT
aud) in ms.
divided attention errors (Divid Att errors).
divided attention omissions (Divid Att omissions).
Flexibility:
median flexibility reaction time (Flex RT) in ms.
flexibility errors (Flex errors).
flexibility performance index (Flex perfom index).
2. SDMT
number of correct answers.
For the assessment of fatigue and depressionwith theWEIMuS,
FSMC, and CES-D, the total values were used for the statistical
analysis.
Results
The statistical analysis was subdivided into three parts. In the first
part, the data of the total sample were analyzed. The second and
third part describes the data of the subsamples of patients with
fatigue and depression, respectively.
Total Sample
Fifty-one patients (11 men, 40 women) with an age between
19 and 51 years (Median: 33.9 9.1) were treated with NTZ
for 1 year. The mean disease duration was 5.3 4.8 years (min-
imum: 0.34 years, maximum: 17.65 years). The average num-
ber of MS medications prescribed prior to NTZ was 1.3 0.8.
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TABLE 2 |Changes in fatigue and depression over the total sample and both
years of observation.
First year of treatment Second year of treatment
Baseline
N= 51
Year 1 (p*)
N= 51
Baseline
N= 31
Year 2 (p*)
N= 31
WEIMuS 30.7514.76a 29.0618.67
(0.19)
30.9414.65 28.8821.18
(0.27)
FSMC 64.7121.19a 64.2923.85
(0.47)
69.5010.66 73.0012.35
(0.31)
CES-D 18.9610.07a 16.8310.21
(0.06)
19.168.97 16.168.95
(0.07)
WEIMuS, Würzburg Fatigue Inventory for MS; FSMC, Fatigue Scale for Motor and
Cognitive Functions; CES-D, Center for Epidemiological Studies-Depression Scale (ger-
man variant, longform).
aMeanSD.
*p-value following paired sample t-test.
The time between baseline and first follow-up assessment after
1 year of treatment was in mean 0.9 0.2 years. About 31 of
these patients (7 men, 24 women) were treated for a sec-
ond year with NTZ (mean time to follow-up from baseline to
year 2 was 2.03 0.4 years). No significant changes were found
in the degree of disability, measured by EDSS from baseline
(EDSS= 3.99 1.55) to year 1 (EDSS= 3.77 1.73; p= 0.06) and
frombaseline (EDSS= 4.13 1.65) to year 2 (EDSS= 3.90 1.68;
p= 0.19) for the total sample.
At baseline, the mean fatigue scores (WEIMuS, FSMC) were
30.75 14.76 and 64.71 21.19, respectively, as shown inTable 2,
ranging from 0 to 64 points in the WEIMuS and 31 to 93 points
in the FSMC. From baseline to year 1, as well as to year 2, no
significant changes were observed (Table 2). In the second year
of treatment, the WEIMuS ranged between 0 and 66 points and
the FSMC ranged between 20 and 91 points.
In depression, measured by the CES-D, only a statistical trend
for significant changes over both time points were observed in the
total sample (Table 2).
The analysis of cognitive parameters (Table 3) showed sig-
nificant changes after 1 year of treatment in 3 out of 10
parameters, and 5 out of 10 parameters in the second year
of treatment. Significant changes were evident in the subtests
alertness [responsiveness (alertness): p< 0.05], and divided atten-
tion of the TAP (median reaction time visual: p< 0.05), and
the SDMT (p< 0.05). After the second year of treatment, the
effect in the divided attention was stable for the visual reac-
tion time (p< 0.001) and extended for the error rate (p< 0.01)
and number of omissions (p= 0.05). Furthermore, the reac-
tion time, as part of cognitive flexibility, significantly changed
from baseline to year 2 (p= 0.05). Above that, the num-
ber of correct answers in the SDMT was significant better
after the second year of treatment in comparison to baseline
(p< 0.01).
Patients with Fatigue
At baseline, 28 patients (54.90%) of the total sample reported
a fatigue syndrome. After the first year of treatment with NTZ,
again, 28 patients (54.90%) of the sample complaint about fatigue,
and after 2 years of treatment still 19 patients (61.29%) reported
a fatigue syndrome. Therefore, no significant changes in fatigue
were observed over the three measurement points (Table 4).
The subgroup of patients with fatigue did not differ in age,
disease duration, EDSS, and cognitive performance from the other
patients (results of the independent t-tests are not shown, because
they are not significant).
Table 4 shows the changes over time in the attention parameters
in the subgroupof patientswith fatigue.After the first year of treat-
ment, 2 out of 10 cognitive parameters were significantly changed
(one trend toward significance in SDMT), and in the second year
3 out of 10 parameters showed significant changes (two trends).
From baseline to year 1, patients with fatigue reached significant
improvements in the subtests alertness (p< 0.05) and flexibil-
ity (p< 0.05). The SDMT showed a trend toward significance
(p= 0.05). In year 2, different parameters of divided attention
(reaction time visual, p< 0.05; omissions, p< 0.05) and flexibility
(reaction time, p= 0.05) significantly improved. The SDMT also
showed a trend toward significance.
Furthermore, changes in the value of depressionwere observed.
At baseline, themeanCES-D (22.04 8.24) reached the cut-off for
a clinical relevant depression. After 1 year of treatment as well as
after 2 years, the CES-D value decreased in mean to 19.19 in year
1 and 17.46 in year 2. Both improvements showed a trend toward
significance.
Patients with Depression
In contrast to the total sample, a clear improvement in the CES-D
value was evident over the observational period. At baseline, 15
patients (29.41%) reported a CES-D value that suggests a clinically
relevant depression, in contrast to 21.56% (11 patients) after 1 year
and 22.58% (7 patients) after 2 years of NTZ treatment. The CES-
D values decreased significantly from baseline to year 1 [t= 2.17
(14), p< 0.05] and from baseline to year 2 [t= 2.81 (8), p< 0.05].
No significant changes were detected between year 1 and year 2
[t= 1.45 (8), p= 0.18].
Changes in cognitive parameters, as shown in Table 5 were
detected similar to the total sample in the divided attention (base-
line to year 1: omissions: p< 0.05; baseline to year 2: visual reac-
tion time: p< 0.05) and flexibility (baseline to year 2: flexibility
reaction time: p< 0.05). In the first year, one cognitive parameter
improved, and in the second year two parameters.
Concerning fatigue, no significant changes were observed in
the observational period. After the first year of NTZ treatment,
the WEIMuS-score was almost identical (Table 5). In the second
year, the score decreased about some points, but without statistical
significance.
Discussion
In this retrospective open label observational study, cognitive
performance, depression, and fatigue of 51 RRMS patients treated
with NTZ over 1 year, and 31 of them treated over 2 years with
NTZ were investigated.
Looking at the total sample, the patients cognitively improved
in different aspects of attention, namely responsiveness (alert-
ness), information processing speed, and divided attention (visual
reaction time) after 1 year of treatment with NTZ. After 2 years of
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TABLE 3 | Changes in different aspects of attention over 2 years of treatment with NTZ.
First year of treatment Second year of treatment
Baseline
N= 51
Year 1 (p*)
N= 51
Baseline
N= 31
Year 2 (p*)
N= 31
AL RTa 279:05 73:11 268:49 54:30(0:13) 294:23 86:15 283:39 65:65 (0:22)
AL RT cueda 277:16 84:01 256.75 37.25 (0.02) 289:23 102:96 269:35 48:74 (0:11)
Divid Att RT visa 884:24 182:45 844.22137.60 (0.02) 912:29 214:89 832.66 165.45 (0.00)
Divid Att RT auda 612:00 91:04 614:04 89:71 (0:42) 626:50 85:56 623:39 91:33 (0:41)
Divid Att errors 2:36 4:06 1:55 2:85 (0:11) 2:75 4:97 1.14 2.01 (0.01)
Divid Att omissions 2:06 0:96 1:72 1:49 (0:12) 2:25 1:95 1.64 1.54 (0.05)
Flex RTa 931:07 778:20 769:97 255:33 (0:07) 1116:31 1040:21 738.78 260.58 (0.05)
Flex errors 3:94 6:80 2:24 2:07 (0:25) 4:83 8:71 1:50 1:46 (0:10)
Flex Perform Index 5:09 6:56 4:18 8:56 (0:39) 4:95 5:11 8:36 7:90 (0:07)
SDMT 49:06 10:01 51.88 7.88 (0.02) 46:67 9:30 53.087.53 (0.01)
a In milliseconds (ms).
All values are presented as meansSD.
AL RT, alertness, reaction time; AL RT cued, alertness reaction time cued; Divid Att RT vis, divided attention reaction time visual; Divid Att RT aud, divided attention reaction time
auditory; Divid Att errors, divided attention errors; Divid Att ommisions, divided attention omission; Flex RT, flexibility reaction time; Flex errors, flexibility errors; Flex Perfom Index,
flexibility performance index; SDMT, symbol digit modalities test.
*p-value following paired sample t-test.
The bold font indicates the statistical significant results.
TABLE 4 | Analysis of cognitive parameters from patients with fatigue at baseline.
Patients with fatigue First year of treatment Second year of treatment
Baseline
N= 28
Year 1 (p*)
N= 28
Baseline
N= 16
Year 2 (p*)
N= 16
AL RTa 277:39 73:20 271:16 65:55 (0:33) 297:75 87:16 280:00 62:01 (0:14)
AL RT cueda 279:61 87:85 255.36 40.29 (0.04) 295:25 110:03 266:19 50:43 (0:12)
Divid Att RT visa 856:41 152:23 834:00 135:99 (0:16) 900:47 186:05 811.20 187.30 (0.03)
Divid Att RT auda 619:26 93:08 627:22 89:85 (0:31) 630:33 92:93 632:00 82:70 (0:46)
Divid Att errors 2:59 4:19 2:26 3:54 (0:46) 2:80 5:26 1:40 2:44 (0:07)
Divid Att omissions 2:11 2:08 1:81 1:54 (0:22) 2:60 2:13 1.67 1.76 (0.02)
Flex RTa 763:25 219:31 778:75 232:57 (0:36) 869:57 269:18 744.00 294.57 (0.04)
Flex errors 2:00 3:26 2:69 2:44 (0:17) 2:43 4:72 1:00 0:82 (0:34)
Flex Perform Index 6:97 6:45 2.17 10.13 (0.03) 6:22 6:52 8:06 9:47 (0:14)
SDMT 48:91 9:85 51:45 7:85 (0:05) 47:00 9:62 52:75 9:16 (0:05)
WEIMuSb 42:19 7:90 41:31 13:18 (0:37) 43:50 8:14 39:50 18:22 (0:19)
FSMCb 70:17 17:01 64:67 26:10 (0:14) 69:50 10:66 73:00 12:35 (0:31)
CES-D 22:04 8:24 19:19 6:63 (0:06) 22:15 8:52 17:46 7:11 (0:06)
a In milliseconds (ms).
All values are presented as meansSD.
bWEIMuS and FSMC: first year: N=16, second year: N=8.
AL RT, alertness, reaction time; AL RT cued, alertness reaction time cued; Divid Att RT vis, divided attention reaction time visual; Divid Att RT aud, divided attention reaction time
auditory; Divid Att errors, divided attention errors; Divid Att ommisions, divided attention omission; Flex RT, flexibility reaction time; Flex errors, flexibility errors; Flex Perfom Index,
flexibility performance index; SDMT, symbol digit modalities test; WEIMuS, Würzburg Fatigue Inventory for MS; FSMC, fatigue Scale for Motor and Cognitive Functions; CES-D, Center
for Epidemiological Studies-Depression Scale.
*p-value following paired sample t-test.
The bold font indicates the statistical significant results.
treatment, additional effects were evident in errors and omissions
in divided attention and the flexibility reaction time.
About 55% of the patients suffered from fatigue at baseline.
This value even increased to 61% in the second treatment year.
Although the fatigue itself was not affected by the treatment,
patients suffering from fatigue showed improvements in respon-
siveness, divided attention, information processing speed, and
flexibility after the first and the second year of treatment.
The data suggests that NTZ may have a positive effect on
depression in patients with RRMS. The CES-D values of the
29% patients with a baseline depression decreased so that after
the first and second year of treatment, only 22% suffered from
depression.
The present results are partially comparable to the hitherto
published data. The main differences are the lack of improvement
in fatigue in the present sample in comparison to the data in the
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TABLE 5 | Analysis of cognitive parameters from patients with depression at baseline.
Patients with depression First year of treatment Second year of treatment
Baseline
N= 15
Year 1 (p*)
N= 15
Baseline
N= 9
Year 2 (p*)
N= 9
AL RTa 265:17 41:55 284:80 63:93 (0:07) 275:39 42:51 282:78 47:98 (0:32)
AL RT cueda 266:47 55:03 268:27 33:95 (0:45) 270:67 63:34 272:89 35:06 (0:45)
Divid Att RT visa 859:43 161:07 827:73 95:46 (0:15) 900:06 194:25 833.67 140.78 (0.02)
Divid Att RT auda 604:93 77:83 614:20 80:100 (0:32) 613:00 55:94 611:67 58:51 (0:48)
Divid Att errors 1:40 1:88 1:00 1:06 (0:14) 1:44 2:35 0:78 1:64 (0:07)
Divid Att omissions 2:07 1:98 1.13 1.12 (0.03) 2:89 2:03 1:44 1:94 (0:04)
Flex RTa 867:81 255:95 820:04 227:88 (0:17) 964:50 305:81 762.14 260.07 (0.03)
Flex errors 2:85 3:51 2:69 2:52 (0:48) 3:14 4:67 1:00 0:82 (0:11)
Flex Perform Index 2:75 4:38  0:31 9:11 (0:12) 4:48 5:35 5:42 6:37 (0:21)
SDMT 51:00 4:24 52:50 2:12 (0:25)
WEIMuS 40:73 8:75 39:18 15:13 (0:35) 43:20 10:37 35:40 19:34 (0:27)
CES-D 30.13 6.26 24.00 11.77 (0.02) 28.67 4.35 18.44 9.98 (0.01)
a In milliseconds (ms).
All values are presented as meansSD.
AL RT, alertness, reaction time; AL RT cued, alertness reaction time cued; Divid Att RT vis, divided attention reaction time visual; Divid Att RT aud, divided attention reaction time
auditory; divid Att errors, divided attention errors; Divid Att ommisions, divided attention omission; Flex RT, flexibility reaction time; Flex errors, flexibility errors; Flex Perfom Index,
flexibility performance index; SDMT, symbol digit modalities test; WEIMuS, Würzburg Fatigue Inventory for MS.
*p-value following paired sample t-test.
The bold font indicates the statistical significant results.
literature and the improved depression. Three published studies
have longitudinally assessed the effect ofNTZ especially on fatigue
as primary outcome variable (34, 36, 41).
Putzki et al. (36) described a contrary effect in comparison to
the present data. In their study, an improvement in fatigue but not
in depression was detected, however, over a shorter observational
period of 6months. In addition, other assessment tools (MFIS,
FSS, BDI) were used, so that the results are not completely com-
parable to the present data. Especially, the BDI encompasses other
aspects of depression as the CES-D. For patients with MS, the
CES-D seems to be more appropriate. Furthermore, the different
treatment periods with NTZ can be a reason for the different
results. Against the background of learning effects, longer time
periods for retesting are recommended.
Svenningson et al. (34) found in a considerably greater sample
(195 patients), an improvement in fatigue over an observational
period of 1 year. In this study comparable to the present study, the
FSMCwas used for assessing fatigue and the CES-D for evaluation
of depression. Patients with a higher fatigue score and a lower
depression score at baseline showed a stronger improvement after
12months of treatment. Fatigue reduced from severe tomoderate,
according to the FSMC, a well reviewed fatigue scale in MS (55).
Secondly and comparable to the present data, an improvement
in depression was observed. The CES-D score improved from
initially 18.3 before treatment to 14.2 after 12months of treatment.
Such a trendwas also observed in the present study (decrease from
18.96 at baseline to 16.83 year 1).
In the study from Iffaldano et al. (41), 100 patients with RRMS
were treated with NTZ over 2 years. As mentioned above, cogni-
tive parameters were assessed by the BRB and Stroop paradigma,
fatigue was measured with the FSS. Fatigue reduced from initially
45 (FSS= 4.01 1.63) to 29% (FSS= 3.61 1.56) after 1 year
of treatment and from 52.8 [28 (53) patients] to 34% [18 (53)
patients] in the second year. Regarding the cognition at baseline,
29% of patients were classified as cognitive impaired and failed
at least in three tests of the BRB and Stroop test. After 1 year of
treatment, the number of cognitive impaired patients decreased
to 19%, and in the subgroup of patients with 2 years of treat-
ment from initially 22.6 to 17%, which was statistical significant.
In contrast to the present data, no effect was found in depression,
measured again with the BDI.
Changes in fatigue as well as in cognition during 12weeks of
treatment were described also by Wilken et al. (35). They used
three different fatigue assessment tools (MFIS, FSS, visual analog
scale). The observed effect improved or remained stable up to
48weeks after initiation of NTZ treatment.
The reason for the different fatigue results between the present
data and previously published data can be the small sample sizes,
especially in the second year of treatment in the present study
as well as the different assessment periods of the used question-
naires. The WEIMuS evaluates the behavior only of the last week,
whereas the FSMC use an overall assessment without time limit.
However, in the literature, predominantly other assessment tools
were used (FSS, MFIS) with again other assessment periods. The
MFIS focuses on the last 4 weeks, the FSS asks for fatigue in
general. Furthermore, there are differences in the content of the
questionnaires. Whereas, the FSS focus on fatigue in general, the
MFIS and FSMC ask for fatigue more specific, and may evaluate
cognitive and physical fatigue separately. Therefore, the compara-
bility of the published results is limited. Recently, the FSMC is the
recommended questionnaire for assessment of fatigue inMS (55).
Other studies with different observational periods describe
comparable to the present data, mostly a positive effect of NTZ
on different aspects of cognition. Lang et al. (32) found significant
improvements in cognition after 6months of treatment with NTZ
in a sample of 29 patients with RRMS. Mainly improvements
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were detected in verbal and non-verbal memory, alertness, quality
of life, depression, and fatigue. A total of 15 (30) assessed param-
eters improved over time, 15 remained equal. These results are
comparable with another sample of 40 patients with RRMS (31),
treated with NTZ over 6months. Cognitive improvements were
demonstrated by using a comprehensive cognitive battery. About
52.5% of all treated patients improved in cognition, 30% have
shown no change, and 17.5% decreased in cognition. The authors
mentioned a strong effect in cognition because of the small cohort.
Therefore, they recommend the use of a comprehensive neuropsy-
chological test battery to assess cognitive functions inMS, relating
to the MACFIMS (56). Mattioli et al. (57) found improvements
in memory and speed processing tasks after 2 years of treatment.
In contrast, an addition to the data in the literature, the present
study focused only on different aspect of attention but confirm
presented results until now.
However, some limiting factors of the present study must be
acknowledged. At first, the sample size in both observational
periods is still small. Limiting factor of all described results from
the literature, as well as from the present results, is the lack
of control groups. From ethical point of view, there are many
barriers for controlled observational studies to assess the effect
of immunomodulatory treatments in patients with MS. To use a
placebo or other drug, in comparison to a treatment group, have
to be exactly examined ethically.
Furthermore, the comparison between NTZ and other
immunomodulatory treatments is very difficult because of the
different activity spectrum. Also, practice effects cannot be
excluded. In the present study, the time difference between the
measurement points is relatively long. Before each attention
assessment, several practice trials were conducted to minimize
practice effects. A recommendation for controlling the practice
effect is an optimal test selection and timing of testing with a
repetitive cognitive testing after a longer time periods, e.g., 6 and
12months (58). A repetitive testing in healthy adults with the
subtests alertness and flexibility (TAP) after 6 and 12months was
not significantly improved (58). Therefore, the present data can be
evaluated as improvement. The results on the depressed subgroup
may be affected by the regression to the mean phenomenon.
In summary, the results of this retrospective open label obser-
vational study show a positive effect of NTZ on different aspects of
attention and depression in patients with highly active RRMS after
1 year of treatment. The effects were stable also in a subgroup of
patients after 2 years of treatment.No effect was detected in fatigue
most likely because of the small sample size or the different assess-
ment tools. Despite, fatigue patients improved in information pro-
cessing speed, divided attention, and cognitive flexibility as well
as in the degree of depression. Treatment with NTZ over longer
periods may stabilize or improve different aspects of cognition
andmood. The observed changes were clinically relevant. Patients
reflected more balance, a better mood, lower sadness, a more
restful sleep andmore power for daily activities, and hobbies. They
were more efficient in daily life, showed a better participation
in social life, and were able to work again in their profession or
a mini-job. The presented results confirm and expand previous
published data especially for longer treatment periods. For the
clinical practice, a regularly assessment of cognition, mood, and
fatigue during the treatment period with NTZ is recommended
for detecting improvement as well as regarding the PML risk. For
a better comparison between study results, a uniform assessment
procedure for the cognitive testing,while treatmentwithNTZ, and
the evaluation of fatigue and depression are needed. Until now for
the evaluation of fatigue, the FSMC is recommended (55).
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